These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18239330)

  • 1. Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia.
    Nagamine T
    Intern Med; 2008; 47(3):181-2. PubMed ID: 18239330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine-induced elevation of plasma triglyceride levels.
    Sheitman BB; Bird PM; Binz W; Akinli L; Sanchez C
    Am J Psychiatry; 1999 Sep; 156(9):1471-2. PubMed ID: 10484969
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
    Pawelczyk T; Pawelczyk A; Rabe-Jablonska J
    J Psychiatr Pract; 2014 Jul; 20(4):301-7. PubMed ID: 25036587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine increases weight and serum triglyceride levels.
    Osser DN; Najarian DM; Dufresne RL
    J Clin Psychiatry; 1999 Nov; 60(11):767-70. PubMed ID: 10584766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.
    Markham-Abedi C; de Leon J
    J Clin Psychiatry; 2006 Sep; 67(9):1473-4. PubMed ID: 17017841
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
    Guina J; Roy S; Gupta A; Langleben DD; Elman I
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.
    eder-Ischia U; Ebenbichler C; Fleischhacker WW
    Essent Psychopharmacol; 2005; 6(2):112-7. PubMed ID: 15765795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
    Balf G
    Am J Psychiatry; 2008 Sep; 165(9):1206-7; author reply 1207. PubMed ID: 18765500
    [No Abstract]   [Full Text] [Related]  

  • 15. Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.
    Horska K; Ruda-Kucerova J; Babinska Z; Karpisek M; Demlova R; Opatrilova R; Suchy P; Kotolova H
    Psychoneuroendocrinology; 2016 Nov; 73():177-185. PubMed ID: 27504985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
    O'Donoghue B; Schäfer MR; Becker J; Papageorgiou K; Amminger GP
    Early Interv Psychiatry; 2014 Aug; 8(3):276-80. PubMed ID: 23968390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.
    Yamamoto K; Fukuda M; Nogawa A; Takahashi E; Miyaoka H
    J Clin Psychiatry; 2007 May; 68(5):802. PubMed ID: 17503998
    [No Abstract]   [Full Text] [Related]  

  • 19. Risperidone-associated increase in triglyceride levels.
    Weinbrenner A; Peus V; Inta D; Englisch S; Zink M
    Am J Psychiatry; 2009 Jan; 166(1):113-4. PubMed ID: 19122019
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
    Newcomer JW; Meyer JM; Baker RA; Eudicone JM; Pikalov A; Vester-Blokland E; McQuade RD; Crandall DT; Carson WH; Marcus RN; L'italien G
    Schizophr Res; 2008 Dec; 106(2-3):300-7. PubMed ID: 18973991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.